Merck chooses France for its first M Lab™ collaboration center in Europe Molsheim is now home to Merck Life Science's first M Lab™ collaboration center in Europe. This new center supports pharmaceutical and biotechnology customers from pre-clinical through full-scale production in non-GMP environment. Molsheim site provides biopharmaceutical manufacturers with a shared,…..
Illustration of lymphocytes attacking cancer cells.©La Jolla Institute How to counteract T cell exhaustion in CAR T cancer therapies? In CAR T cell therapies, a patients' own T cells are removed and genetically engineered to better recognize cancer cells. The cells are then returned to the patient's body, where…..
FEATURE STORY ● Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy GENE THERAPY ● Dual AAV-mediated gene therapy restores hearing in a DFNB9 mouse model ● Long-term correction of hemophilia B using adenoviral delivery of CRISPR/Cas9 RARE DISEASES ● Characterization and treatment of congenital thrombotic thrombocytopenic purpura ● Targeting angiogenesis in…..
1eres Journées Polepharma de microbiomique Le cluster de production pharmaceutique Polepharma organise ses premières journées de microbiomique les 9 et 10 avril prochains à l'UFR Santé de l'université de Rouen. Le programme a été co-construit entre académiques, start-up, PME et grands industriels de la pharma présents au sein du premier…..
FEATURE STORY ● Luxturna®: FDA documents reveal the value of a costly gene therapy GENE THERAPY ● The application of Adeno-Associated Viral vector gene therapy to the treatment of Fragile X Syndrome ● Adeno-associated virus vector as a platform for gene therapy delivery ● Integrative analysis of pooled CRISPR genetic screens…..
Antibiotic development increased, but still insufficient While the pipeline of new antibiotics has improved over the past six years, momentum in the development of new infection-fighting agents remains inadequate and could take a significant downturn without new incentives, a report released in Clinical Infectious Diseases shows. This report, an update of progress…..
Digital fusion: how smart collaborations will drive the healthcare revolution Convergence of digital technology and healthcare – digital health – has become a key driver of change for healthcare systems globally, with the mass adoption of digital technologies set to revolutionise healthcare and patient wellbeing. Payors and healthcare and life…..
Imabiotech, a French CRO based in Lille (France) and in Boston (USA), is expanding its range of services. This company is offering innovative imaging services and software to the pharmaceutical research sector. These services are based on histology combined to label free molecular imaging (Quantitative Mass Spectrometry Imaging, QMSI) . This technology…..
FEATURE STORY ● AllergoOncology: microbiota in allergy and cancer - an EAACI position paper BASIC SCIENCE ● The 1000IBD project: multi-omics data of 1000 inflammatory bowel disease patients ● Effect of the nursing mother on the gut microbiome of the offspring during early mouse development ● Enhancement of the gut barrier integrity by…..
An inhalable form of mRNA for the treatment of lung diseases About 80 RNA therapeutics are currently in clinical trial. Among these drug candidates, mRNA, which can induce cells to produce therapeutic proteins, holds great promise for treating a variety of diseases. The biggest obstacle to this approach so far…..
- 1
- 2
- 3
...
- 32
- Page Suivante
Partenaires
